Comments
Loading...

MaxCyte

MXCTNASDAQ
Logo brought to you by Benzinga Data
$3.45
-0.04-1.15%
At close: -
$3.48
0.030.87%
After Hours: 9:29 AM EDT
Consensus Rating1
Buy
Highest Price Target1
$11.00
Lowest Price Target1
$7.00
Consensus Price Target1
$8.67

MaxCyte (NASDAQ:MXCT) Stock, Analyst Ratings, Price Targets, Forecasts

MaxCyte Inc has a consensus price target of $8.67 based on the ratings of 3 analysts. The high is $11 issued by Stephens & Co. on April 23, 2024. The low is $7 issued by Craig-Hallum on November 29, 2023. The 3 most-recent analyst ratings were released by Stephens & Co., Stephens & Co., and BTIG on April 23, 2024, March 13, 2024, and March 13, 2024, respectively. With an average price target of $10 between Stephens & Co., Stephens & Co., and BTIG, there's an implied 187.36% upside for MaxCyte Inc from these most-recent analyst ratings.

Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Stephens & Co.
BTIG
Craig-Hallum

1calculated from analyst ratings

Analyst Ratings for MaxCyte

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for MaxCyte (MXCT) stock?

A

The latest price target for MaxCyte (NASDAQ:MXCT) was reported by Stephens & Co. on April 23, 2024. The analyst firm set a price target for $11.00 expecting MXCT to rise to within 12 months (a possible 216.09% upside). 4 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for MaxCyte (MXCT)?

A

The latest analyst rating for MaxCyte (NASDAQ:MXCT) was provided by Stephens & Co., and MaxCyte reiterated their overweight rating.

Q

When was the last upgrade for MaxCyte (MXCT)?

A

There is no last upgrade for MaxCyte

Q

When was the last downgrade for MaxCyte (MXCT)?

A

There is no last downgrade for MaxCyte.

Q

When is the next analyst rating going to be posted or updated for MaxCyte (MXCT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MaxCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MaxCyte was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.

Q

Is the Analyst Rating MaxCyte (MXCT) correct?

A

While ratings are subjective and will change, the latest MaxCyte (MXCT) rating was a reiterated with a price target of $11.00 to $11.00. The current price MaxCyte (MXCT) is trading at is $3.48, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch